Clinical proton MR spectroscopy of neurodegenerative disease in childhood

A. A. Tzika, W. S. Ball, D. B. Vigneron, R. S. Dunn, D. R. Kirks, R. A. Zimmerman, J. Valk, Z. Wang

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


PURPOSE: To determine the contribution of MR spectroscopy in the assessment of childhood neurodegenerative disease. METHODS: Fifty-one subjects (7 weeks to 17 years of age), 22 with either hereditary (n = 16) or acquired (n = 6) neurodegenerative disorders and 29 age-matched control subjects, were studied with combined proton MR spectroscopy and MR imaging. Single-voxel (2.0-8.0 cc) MR spectra were acquired at 1.5 T, with either short-echo-stimulated echoes and/or long-echo spin echoes. RESULTS: MR spectra exhibited signals from n-acetyl-, creatine-, and choline-containing compounds, neurotransmitters (glutamate), intracellular mediators (inositols), and glycolytic products (lactate). Abnormal MR spectra in neurodegenerative disorders reflected: demyelination, neuronal loss, and gliosis (increased mobile lipid presence and reduction of n-acetylaspartate to choline); metabolic acidosis (lactate accumulation); and neurotransmitter neurotoxicity (increased glutamate, glutamine, and inositols). CONCLUSION: Proton MR spectroscopy may complement MR imaging in diagnostic assessment and therapeutic monitoring of neurodegenerative disorders.

Original languageEnglish (US)
Pages (from-to)1267-1284
Number of pages18
JournalAmerican Journal of Neuroradiology
Issue number6
StatePublished - Jan 1 1993

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology


Dive into the research topics of 'Clinical proton MR spectroscopy of neurodegenerative disease in childhood'. Together they form a unique fingerprint.

Cite this